News / Taiwan / economic_daily
Jinghua Biomedical Lists on Taipei Exchange, Targeting Capacity Expansion and Global Growth
Health Services · Medical/Nursing Services · economic_daily · 2026-10-15
7806
Jinghua Biomedical officially listed on the Taipei Exchange at 55 TWD per share, with plans to double production capacity through new facilities and AI integration.
What Happened
Listing and Strategy: Jinghua Biomedical officially debuted on the Taipei Exchange at an offering price of 55 TWD. Chairman Chen Chun-hung stated that the company aims to leverage the launch of its second factory and smart warehousing to double production capacity, positioning itself as a premier technical partner for global health brands.
Digital Transformation: The company is aggressively adopting Industry 4.0 standards by integrating AI into its R&D and production processes. By connecting ERP and MES systems, Jinghua aims to achieve full digital traceability and quality control, while simultaneously reducing raw material costs through direct sourcing to protect margins.
Product Pipeline: A key focus for the company is the high-value development of deer antler peptide products, slated for launch in late 2026 to target the joint health market. Furthermore, the company is developing premium ingredients like bird's nest nanovesicles and pursuing additional health food certifications to strengthen its competitive moat.
Global Expansion: Jinghua is actively expanding into Southeast Asian and North American markets by participating in international trade shows and leveraging existing client networks. The company has set a target for international revenue to reach 5% by 2028, aiming to export its CDMO capabilities and establish a new growth trajectory post-listing.